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Enterococci have emerged as important nosocomial pathogens due to their resistance to the most commonly used antibiotics. 
Alternative treatments or prevention options are aimed at polysaccharides and surface-related proteins that play important roles in 
pathogenesis. Previously, we have shown that 2 Enterococcus faecium proteins, the secreted antigen A and the peptidyl-prolyl cis-
trans isomerase, as well as the Enterococcus faecalis polysaccharide diheteroglycan, are able to induce opsonic and cross-protective 
antibodies. Here, we evaluate the use of glycoconjugates consisting of these proteins and an enterococcal polysaccharide to develop 
a vaccine with broader strain coverage. Diheteroglycan was conjugated to these 2 enterococcal proteins. Rabbit sera raised against 
these glycoconjugates showed Immunoglobulin G titers against the corresponding conjugate, as well as against the respective protein 
and carbohydrate antigens. Effective opsonophagocytic killing for the 2 sera was observed against different E. faecalis and E. faecium 
strains. Enzyme-linked immunosorbent assays against whole bacterial cells showed immune recognition of 22 enterococcal strains 
by the sera. Moreover, the sera conferred protection against E. faecalis and E. faecium strains in a mouse infection model. Our results 
suggest that these glycoconjugates are promising candidates for vaccine formulations with a broader coverage against these nosoco-
mial pathogens and that the evaluated proteins are potential carrier proteins.
Keywords. Vaccine; glycoconjugate; carrier protein; capsular polysaccharide; diheteroglycan; enterococcal proteins; Enterococcus 
faecalis; Enterococcus faecium; opsonophagocytic assay; mouse infection model.
The increasing prevalence of pathogens exhibiting antimicro-
bial resistance has encouraged the identification of novel 
vaccine targets [1]. In addition to preventing infections, vacci-
nation can help to reduce the use of broad-spectrum antibiotics 
by providing protection to individuals at risk [2, 3].
Enterococcus faecalis and Enterococcus faecium, respectively, 
are the third and fourth most commonly isolated nosocomial 
pathogens worldwide [4, 5]. The increased prevalence of entero-
cocci as nosocomial pathogens has been mainly attributed to 
their antimicrobial resistances, their ability to acquire virulence 
factors, and to form biofilms on indwelling devices [6]. Several 
cell-surface polysaccharides and protein structures have been 
proposed as potential vaccine candidates to prevent and/or treat 
enterococcal infections [7]. Among capsular polysaccharides, 
diheteroglycan (DHG) has been demonstrated to elicit opsonic 
and protective antibodies against E. faecalis and is therefore an 
attractive immunogenic antigen for vaccine development [8]. 
DHG, present in E.  faecalis CPS-C and CPS-D strains, seems 
to contribute to enterococcal pathogenicity by conferring re-
sistance to opsonophagocytosis and masking antigens from 
detection by the host’s immune system [9]. This highlights the 
importance of capsular DHG in pathogenic interactions and 
supports its use as an antigen for vaccine development [10]. 
For E. faecium, several cell-surface–associated protein antigens 
have been proposed as vaccine candidates [11–13]. Cell wall–
associated proteins have been proven to play important roles 
in adhesion and invasion of the host cells [14]. The secreted 
antigen A protein (SagA) is well conserved among E.  faecium 
strains and has been demonstrated to be associated with biofilm 
formation, stress response, and adhesion to extracellular ma-
trix proteins [11, 15]. The peptidyl-prolyl cis-trans isomerase 
protein (PpiC) is involved in β-lactam antibiotic resistance and 
has been shown to confer resistance to high salt concentrations 
[16]. In previous studies, we have demonstrated that both SagA 
and PpiC are able to induce opsonic and cross-protective anti-
bodies that target enterococci [11, 12].
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Owing to the normally T-cell–independent immune response 
against polysaccharides, conjugation to a carrier protein is nec-
essary to activate T cells to induce an effective immune humoral 
response [17]. Currently, several licensed glycoconjugate vac-
cines have shown to be safe and successful in the prevention of 
infectious diseases [18]. However, the increasing number of con-
jugate vaccines relying on the same carrier proteins could cause 
a reduced immune response against polysaccharide antigens, 
resulting in vaccine interferences [19]. Therefore, in this study 
we evaluated the use of SagA and PpiC from E. faecium as car-
rier proteins conjugated to DHG from E. faecalis, to develop a 
cross-species vaccine with broad coverage against the 2 clini-
cally most important enterococcal species.
METHODS
Bacterial Strains and Culture Conditions
E. faecalis type 2 was used to evaluate the polysaccharide com-
ponent of the conjugates. To study the protein component in 
the conjugate we used the vancomycin-resistant clinical isolate 
E. faecium 11236/1. For cross-reactivity tests, the enterococcal 
strains used are listed in Figure 1. Strains were grown at 37°C 
in tryptic soy agar (Carl Roth). For polysaccharide purifica-
tion E. faecalis type 2 was grown in Columbia broth (Becton-
Dickinson) with 2% glucose at 37°C until an OD600 of 0.8 was 
reached. For production of recombinant proteins, Escherichia 
coli M15/pQE30 protein-gene strains were cultured under 
shaking at 37°C in Luria/Miller medium (Carl Roth) supple-
mented with 100 μg/mL ampicillin and 25 μg/mL kanamycin.
Semisynthesis of Glycoconjugates
Antigens DHG, SagA, and PpiC were produced and purified 
as described previously (Supplementary Materials) [8, 11, 12]. 
After the purification procedure, rSagA and rPpiC were used 
for conjugation at 5  mg/mL. DHG was covalently coupled to 
the proteins as described by Lees et al, using the cyanylating re-
agent 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate 
(CDAP; Sigma-Aldrich) at 100  mg/mL in acetonitrile [29]. 
A solution of 1 mg of DHG in 100 µL of ultrapure water was 
slowly mixed with 10 µL of CDAP. After 30 seconds, 15 µL of 
0.2 M trimethylamine was added. Final coupling was done by 
adding 1  mg of protein to the mixture, and the reaction was 
incubated overnight at room temperature. The glycoconjugates 
(DHG-SagA and DHG-PpiC) were cleaned up with an Amicon 
ultrafiltration device with a 100-kDa membrane (Merck-
Millipore). The correct conjugation process was assessed by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot (Supplementary Materials). 
Sugar and protein content were determined by hexose and 
Bradford assays to establish the polysaccharide to protein ratio 
in the glycoconjugates (Supplementary Materials).
Strain
CPS
Serotype(s) Source (Specimen)
Van
Resistant
Opsonophagocytic
Assay α-DHG-PpiC α-DHG-SagA α-DHG α-Ppic α-SagA Reference
E. faecalis
Type 2 C Clinical (urine) No OPA 60.78 ± 2.23 56.98 ± 3.56 50.18 ± 1.13 1.09 ± 0.02 1.16 ± 0.16 [20]
V583 C Clinical (blood) Yes OPA 3.66 ± 0.18 3.14 ± 0.06 9.09 ± 0.02 1.93 ± 0.04 1.59 ± 0.04 [21]
FA2-2 C Clinical No OPA 3.31 ± 0.03 4.52 ± 0.10 5.24 ± 0.45 2.24 ± 0.03 1.76 ± 0.01 [22]
Type 14 C Clinical No SRPA 3.30 ± 0.051 3.28 ± 0.02 5.23 ± 0.13 2.85 ± 0.26 1.34 ± 0.02 [20]
Type 21 C Clinical (feces) No CMP 9.39 ± 0.09 6.86 ± 0.27 10.37 ± 0.08 1.83 ± 0.04 1.55 ± 0.05 [20]
Type 6 C, D Clinical No CMP 1.64 ± 0.02 1.73 ± 0.10 5.94 ± 0.03 2.09 ± 0.12 1.60 ± 0.07 [20]
Type 5 D Clinical (urine) No OPA 2.26 ± 0.05 1.73 ± 0.03 3.54 ± 0.08 1.19 ± 0.01 1.04 ± 0.02 [20]
Type 18 D NCTC 8730 No OPA 3.61 ± 0.35 2.70 ± 0.42 8.55 ± 0.03 1.92 ± 0.02 1.46 ± 0.01 [20]
68114 D Clinical No CS 2.26 ± 0.04 2.40 ± 0.13 5.77 ± 0.06 1.75 ± 0.06 1.72 ± 0.05 [23]
12030 A Clinical No SRPA 3.05 ± 0.18 2.18 ± 0.06 2.03 ± 0.07 2.60 ± 0.03 1.84 ± 0.02 [24]
Type 7 A Clinical No SRPA 2.01 ± 0.11 2.14 ± 0.11 1.87 ± 0.03 2.74 ± 0.11 1.63 ± 0.04 [20]
12107 B Clinical No CMP 4.08 ± 0.11 5.44 ± 0.21 7.15 ± 0.09 2.56 ± 0.14 1.77 ± 0.01 [25]
OG1RF B Oral (human) No CS 2.63 ± 0.01 4.82 ± 0.14 6.73 ± 0.17 2.11 ± 0.05 1.66 ± 0.02 [26]
E. faecium
11236/1 NA Clinical (feces) Yes OPA 2.22 ± 0.08 1.93 ± 0.03 1.24 ± 0.06 4.28 ± 0.05 2.80 ± 0.10 This study
1230933 NA Clinical (blood) Yes OPA 2.11 ± 0.12 2.71 ± 0.07 1.13 ± 0.14 2.54 ± 0.03 3.38 ± 0.20 [27]
1231408 NA Clinical (blood) No SRPA 1.99 ± 0.06 2.62 ± 0.07 1.20 ± 0.08 2.25 ± 0.06 2.90 ± 0.053 [27]
1231410 NA Clinical (SSTI site) Yes CMP 2.07 ± 0.03 6.76 ± 0.12 1.16 ± 0.04 3.00 ± 0.03 9.99 ± 0.43 [27]
757875 NA Clinical Yes OPA 1.97 ± 0.01 3.13 ± 0.11 1.18 ± 0.03 1.86 ± 0.06 2.77 ± 0.04 [24]
E1162 NA Clinical (blood) No SN 2.28 ± 0.048 9.43 ± 0.47 1.13 ± 0.09 3.78 ± 0.06 16.04 ± 0.14 [27]
E155 NA
NA
NA
Clinical (feces) Yes SRPA 1.92 ± 0.14 3.18 ± 0.10 1.26 ± 0.04 2.66 ± 0.03 5.45 ± 0.17 [28]
E980 Community (feces) No CS 1.58 ± 0.06 2.87 ± 0.04 1.17 ± 0.07 2.14 ± 0.01 5.53 ± 0.07 [27]
U0317 Clinical (urine) No OPA 2.19 ± 0.10 2.46 ± 0.15 1.36 ± 0.14 1.98 ± 0.03 2.58 ± 0.05 [27]
Ratio: <1.4 1.4 ≤X<2 2 ≤X<4 4 ≤X<8 8 ≤X<15 X>15
ELISA Immunoreactivity, Geometric Mean Absorbance
(Immune/Preimmune) ± SD
Figure 1. Immunoreactivity detected by whole-bacterial-cell enzyme-linked immunosorbent assays (ELISAs) for α-DHG-PpiC, α-DHG-SagA, and unconjugated sera against 
diverse Enterococcus faecalis and Enterococcus faecium strains. CMP, complement-mediated phagocytosis in the opsonophagocytic assay; CPS, capsular polysaccharide; CS, 
susceptible to complement in the opsonophagocytic assay; NA, not applicable; OPA, possible to test by the opsonophagocytic assay; SRPA, susceptible to rabbit preimmune 
antibodies in the opsonophagocytic assay; SSTI, skin and soft-tissue infection; Van, vancomycin.
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Rabbit Immunzations
Rabbit immune sera raised against DHG from E. faecalis type 
2 (α-DHG), SagA (α-SagA), and PpiC (α-PpiC) have been pre-
viously described [8, 11, 12]. For DHG-PpiC and DHG-SagA, 
New Zealand white rabbits were vaccinated with 2 subcuta-
neous injections of 10 µg of conjugate in incomplete Freund’s 
adjuvant given 2 weeks apart. An intravenous injection of 5 µg 
of the conjugate was given 7 days later, followed by 2 more in-
travenous injections of 5 µg delivered 2 days apart from each 
other. On day 35, a test serum was collected, and 7 and 14 days 
later intravenous boosts with 5  µg of antigen were adminis-
tered. On day 56, a  terminal immune serum was collected 
from each rabbit. All sera were heat inactivated at 56°C for 30 
minutes. Terminal immune  sera raised against the conjugates 
were designated α-DHG-PpiC and α-DHG-SagA. The anti-
bodies were purified using an rProtein A  GraviTrap column 
(GE Healthcare) in accordance with the manufacturers’ in-
structions. Immunoglobulin G (IgG) contents were measured 
by enzyme-linked immunosorbent assays (ELISAs) in purified 
and unpurified sera (Supplementary Materials).
IgG Titer Measurement
The antigens DHG-SagA, DHG-PpiC, DHG, SagA, and PpiC 
(prepared at 1 µg/mL in 0.2 M sodium carbonate/bicarbonate 
buffer) were used to coat Nunc-immuno Maxisorp 96-well 
plates (Thermo-Fisher Scientific) overnight at 4°C. Wells were 
washed 3 times with 200  µL of PTB (phosphate-buffered sa-
line [PBS] with 0.05% Tween 20 at pH 7.4). Wells were blocked 
with 200 µL of blocking buffer (3% bovine serum albumin in 
PBS) at 37°C for 1 hour and washed 3 times with 200  µL of 
PTB. Sera were adjusted to 50  µg/mL IgG in blocking buffer, 
and 2-fold serial dilutions were made in the same buffer. After 
that, 100 µL serum dilutions were added in triplicate, and plates 
were incubated for 1 hour. Wells were washed 3 times with 
200  µL of PTB. Afterward, 100  µL of alkaline phosphatase–
conjugated anti-rabbit IgG produced in goat (Sigma-Aldrich) 
at 1:1000 were added to each well, and plates were incubated 
for 1 hour. Finally, wells were washed 4 times with 200 µL of 
PTB, and 100  µL of the p-nitrophenyl phosphate substrate 
(Sigma-Aldrich) at 1  mg/mL in glycine buffer were added to 
each well before incubation for 30 minutes. To stop the reaction, 
50 µL/well of 3 M NaOH were added, and the absorbance was 
measured at 405 nm in an ELISA reader (Synergy H1 Hybrid 
reader, BioTek). Titers were calculated as follows: for each 
serum sample, the linear relationship between the OD and the 
log10[dilution factor] was used to extrapolate the intercept of an 
absorbance of 0.3 for each test, and this was taken as the ELISA 
end point titer.
Opsonophagocytic Assay (OPA)
OPAs were performed as previously described [11]. The bacte-
rial strain, complement, white blood cells and rabbit sera were 
prepared individually prior the assay. The bacterial suspension 
was diluted in RPMIF (Roswell Park Memorial Institute 1640 
medium with 15% fetal bovine serum) to yield a final concen-
tration of 2 ×  106 cells/mL. Lyophilized baby rabbit comple-
ment (Cedarlane) was dissolved in RPMIF at 6.7%, absorbed 
for 60 minutes at 4°C with the target bacterial strain, and steril-
ized by filtration before use. Rabbit sera or purified antibodies 
were diluted in RPMIF at the indicated concentration. White 
blood cells were freshly prepared from human blood specimens 
and adjusted to a final concentration of 2 × 106 cells/mL. For 
opsonophagocytic inhibition assays, purified antibodies were 
inhibited with the corresponding DHG-protein conjugate, pro-
tein alone, or DHG alone. Concentrations ranging from 0.08 to 
200µg/mL of inhibitor were incubated overnight at 4°C with an 
equal volume of a purified antibody at the indicated concentra-
tion. After incubation, the mixture of inhibitor/serum was used 
as a source of antibodies in the OPA as described above.
Whole-Bacterial-Cell ELISA
Immunoreactivity against the enterococcal strains listed in 
Figure 1 was measured by whole-cell ELISAs with α-DHG, 
α-protein, and α-DHG-protein sera. Bacteria were grown 
on tryptic soy agar plates and incubated overnight at 37°C. 
Colonies were collected from the plate and inoculated in 50 mL 
of tryptic soy broth at an OD650 of 0.1. Cultures were grown to 
an OD650 of 0.4 and harvested by centrifugation (at 7450 xg and 
4°C for 10 minutes). Cell pellets were washed twice with 50 mL 
of PBS, resuspended in 25 mL of 8% paraformaldehyde (Sigma-
Aldrich) in PBS, and incubated at 4°C for 30 minutes under 
gentle shaking. Then, cells were washed twice with 25  mL of 
PBS and finally resuspended in 10  mL of 0.2 M sodium car-
bonate/bicarbonate buffer. Nunc-immuno Maxisorp 96-well 
plates were coated with 100 µL/well of cell suspension and in-
cubated overnight at 4°C. ELISAs were performed as described 
above to measure the IgG titer. The immunoreactivity with a 
specific serum sample  was calculated as the ratio of absorb-
ance of the terminal immune serum to the absorbance of the 
preimmune serum.
Intravenous Mouse Infection Model
The mouse sepsis infection model was performed as described 
previously with some modifications [13, 30, 31]. Briefly, male 
BALB/c mice (weight range, 20–25 g; Harlan, Italy) were ran-
domly separated into 4 groups of 6 and intraperitoneally in-
jected 3 times with 200  µL of either normal rabbit serum, 
α-DHG-PpiC, or α-DHG-SagA 48 hours before, 24 hours be-
fore, and 4 hours after the bacterial challenge. Overnight cul-
tures of E. faecalis type 2 and vancomycin-resistant E. faecium 
11236/1 grown in brain heart infusion broth (Sigma-Aldrich) 
supplemented with 40% heat-inactivated horse serum (Sigma-
Aldrich) were centrifuged, and the resulting pellets were re-
suspended in sterile PBS to achieve final concentrations of 109 
bacteria/mL. Mice were first anaesthetized with 100 mg/g keta-
mine (Merial) and 12 mg/g xylazine (Bayer) via intraperitoneal 
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injection. Aliquots of 100 µL from each strain suspension were 
injected intravenously into the corresponding group of mice. 
The animals were monitored twice per day before being euthan-
ized by cervical dislocation 48 hours after the bacterial chal-
lenge. Kidneys and livers were aseptically removed, weighed, 
and homogenized in PBS for 120 seconds at high speed in a 
Stomacher (Pbi International). Serial dilutions were plated onto 
Enterococcus Selective Agar (Fluka Analytical) to determinate 
the number of colony-forming units.
Statistical Analysis
For statistical analysis, Prism, version 7.00 (GraphPad), was 
used. The percentage of opsonophagocytic killing and absorb-
ance detected by whole-cell ELISA was expressed as the geo-
metrical mean and standard error of the mean. For OPAs and 
opsonophagocytic inhibition assays, statistical significance was 
determined by the nonparametric Kruskal-Wallis test, followed 
by the Dunn post hoc test for multiple comparisons. Results 
of in vivo experiments were subjected to statistical analysis 
by using 1-way analysis of variance with a Dunnett multiple 
comparison test. P values of <.05 were considered statistically 
significant.
Ethics Statement
Rabbits were housed, immunized, and had serum samples 
collected by Biogenes (Berlin, Germany), in accordance with 
national and international animal welfare regulations. Rabbit 
immunizations were performed under approval and with assur-
ance from the National Institutes of Health Office of Laboratory 
Animal Welfare (identifier A5755-01). Mouse experiments 
were conducted under a protocol approved by the Institutional 
Animal Use and Care Committee at Università Cattolica del 
Sacro Cuore, Fondazione Policlinico Universitario Agostino 
Gemelli IRCCS, and authorized by the Italian Ministry of Health 
(protocol 1F295.37, 11/05/2017; authorization 903/2017-PR, 
11/05/2017) according to Legislative Decree 116/92, which 
implemented the European Directive 86/609/EEC on labora-
tory animal protection in Italy.
RESULTS
DHG-Protein Conjugate Synthesis
After purifying the conjugates, protein and sugar amounts in 
the conjugates were determined. The ratios of protein to poly-
saccharide in the DHG-PpiC and DHG-SagA conjugates were 
1:8.7 and 1:7.5, respectively. To verify the conjugation, gels used 
in SDS-PAGE were either stained with InstantBlue or Stains-
All or were blotted into a membrane for Western blot analysis 
(Supplementary Materials). All glycoconjugates showed broad 
bands, with staining showing greater molecular weights than 
those of the unconjugated polysaccharide and protein. Western 
blot analysis using sera raised against the unconjugated DHG 
and proteins showed that the conjugates were recognized by 
these antibodies. This demonstrates that, in the polysaccharide 
and protein parts of the conjugate, the important immunogenic 
epitopes remained intact after the conjugation process.
Specific Antibodies Were Generated During Immunization
To determine antibody titers raised against DHG, carrier pro-
teins, or DHG-protein conjugates during immunization, sera 
collected at different time points of the immunization reg-
imen were analyzed against the unconjugated molecules and 
glycoconjugates. Figure 2 shows that increasing amounts of IgG 
antibodies against all evaluated molecules were generated during 
the immunization procedure. The IgG titer against DHG-PpiC 
with the terminal immune serum α-DHG-PpiC was 11% higher 
than the titer against DHG-SagA exhibited by α-DHG-SagA ter-
minal immune serum (Figure 2C). Thereafter, in all subsequent 
experiments, terminal immune serum α-DHG-SagA was used 
1.1 times more concentrated than that from α-DHG-PpiC ter-
minal immune serum, and preimmune serum were used at the 
same IgG concentration as the terminal immune serum.
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Figure 2. Immunoglobulin G (IgG) titer curves of sera raised against different DHG-protein glycoconjugates. Rabbit sera α-DHG-PpiC (solid line) or α-DHG-SagA (dotted 
line) were examined during the immunization schedule for specificity toward the native DHG (A), the respective carrier proteins SagA and PpiC (B), and the respective different 
DHG-protein glycoconjugates (C). IgG titers were measured by enzyme-linked immunosorbent assays, using 1 µg per well of antigen. Rabbit sera were plated in 2-fold serial 
dilutions, starting at an IgG concentration of 50 µg/mL.
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Raised Antibodies Mediate Opsonophagocytosis
Antibodies targeting DHG were tested using E.  faecalis type 
2 because this strain was previously demonstrated to possess 
this antigen and to be targeted by α-DHG opsonic antibodies 
[8]. Vancomycin-resistant clinical isolate E.  faecium 11236/1 
was used as target strain for anti-protein antibodies, since most 
E. faecium strains encode and expresses the 2 immunogenic pro-
teins SagA and PpiC [11, 12]. Percentages of opsonophagocytic 
killing  against E. faecalis Type 2 and E. faecium 11236/1 elicited 
by α-DHG-PpiC and α-DHG-SagA were comparable and con-
centration dependent (Figure 3). Control preimmune sera from 
α-DHG-protein did not significantly mediate opsonophagocytic 
killing.
Antibodies Are Specific Against DHG or Protein Antigens
Specificity was evaluated by incubating the antibodies with 
different amounts of unconjugated molecules. As observed in 
Figure 4A, opsonophagocytic killing of E.  faecalis type 2 by 
α-DHG, α-DHG-PpiC, and α-DHG-SagA sera was inhibited by 
high amounts of DHG and restored at lower amounts of an-
tigen. For vancomycin-resistant E.  faecium 11236/1, activities 
of α-PpiC, α-SagA, α-DHG-PpiC, and α-DHG-SagA sera were 
inhibited in a dose-dependent manner with increasing amounts 
of rPpiC or rSagA proteins (Figure 4B).
Antibodies Against Conjugates Are Cross-reactive Against Other 
E. faecium and E. faecalis Strains
Cross-reactivity of antibodies targeting DHG was evaluated 
against E. faecalis from serotypes CPS-C and CPS-D, ie E. faecalis 
V583 and E. faecalis type 5, respectively, strains that are suscep-
tible to α-DHG sera in OPA (Figure 5A and 5B) [8]. Antibodies 
targeting proteins in the α-DHG-protein sera  were evalu-
ated against E.  faecium E155 and E.  faecium 757875 (Figure 
5C and 5D), previously reported to be effectively phagocyt-
osed by α-SagA and α-PpiC sera [11, 12]. α-SagA, α-PpiC, 
and α-DHG-protein mediated opsonophagocytic killing of 
the 4 enterococcal strains tested, while α-DHG only mediated 
the opsonophagocytosis of E.  faecalis strains. Nevertheless, 
higher opsonophagocytic killing activities against the E. faecalis 
strains were observed for α-DHG-protein sera when compared 
to α-protein sera. To further examine the cross-reactivity and 
to determine surface availability of our antigenic determin-
ants in a broader bacterial collection, we performed whole cell 
ELISAs (Figure 1). α-DHG-protein sera recognized all enter-
ococcal strains tested, whereas α-DHG sera only recognized 
E. faecalis strains. Even though some immunoreactivity with the 
E. faecalis strains was observed for α-protein sera, it was much 
lower than the one observed with α-DHG-protein sera. As ex-
pected, E. faecium strains immunoreacted only with α-protein 
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Figure 3. Opsonophagocytic killing activity of anti glycoconjugate rabbit sera against prototype enterococcal strains. Enterococcus faecalis type 2 (A) and vancomycin-
resistant Enterococcus faecium 11236/1 (B) were tested with antibodies raised against the conjugates DHG-PpiC (horizontal stripes) and DHG-SagA (vertical stripes), used at 
the same titer concentration ratio. The absolute immunoglobulin G (IgG) concentration of the sera is shown in the x-axis. Sera raised against the native DHG (black bar) and 
the recombinant proteins PpiC (diagonal stripes) and SagA (square grids) were used as controls. The effectiveness of opsonophagocytic killing by the anti-conjugate rabbit 
sera obtained from terminal immune sera (terminal) was compared to that by the preimmune rabbit sera (preimmune; lighter color). Comparisons of preimmune and terminal 
immune sera  at the same concentration were made by the nonparametric Kruskal-Wallis test, followed by the Dunn multiple comparisons post hoc test. Bars and whiskers 
denote mean values ± standard errors of the mean. NS, not significant (P ≥ .05). *P < .05, **P < .01, ***P < .001, and ****P < .0001.
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and α-DHG-protein antibodies. For E.  faecalis strains, some 
opsonophagocytic killing activity was observed by α-protein, as 
previously described [11, 12].
Antibodies Against Conjugates Promotes Clearance of Bacteria in Mice
To evaluate the protective efficacy of antibodies raised against 
the DHG-protein conjugates, we used a mouse infection 
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model, in which we challenged mice with E. faecalis type 2 and 
vancomycin-resistant E. faecium 11236/1. For E. faecalis type 2, 
the protection conferred by the sera raised against the different 
DHG-protein conjugates was comparable in the livers and kid-
neys (Figure 6A and 6B) and significantly better than that con-
ferred by control sera (normal rabbit sera). Mice challenged 
with E.  faecium 11236/1 were protected in the livers (Figure 
6C) when passively vaccinated with the α-DHG-protein sera. 
However, no protection in mouse kidneys against the E. faecium 
11236/1 was observed for any of the sera (data not shown).
DISCUSSION
Enterococci are the second most common cause of noso-
comial infections [32]. The pathogenicity of enterococci is 
greatly enhanced by their genetic versatility and ability to ac-
quire antimicrobial resistance and virulence determinants [33]. 
Immunoprophylactic approaches are of great importance and 
could provide protection against infections caused by antibiotic-
resistant bacteria [3]. Therefore, the development of a vaccine 
against enterococci would be a valuable approach to fight this 
opportunistic pathogen [7].
Key points in the development of an antibacterial vaccine have 
been already pursued in enterococci, such as serotyping and 
elucidation of carbohydrates responsible of serodiversity. For 
E.  faecalis, 4 different serotypes (CPS A–D) have been previ-
ously described, and 2 polysaccharides responsible for most of 
this serodiversity have been proposed as antigens for the de-
velopment of an enterococcal vaccine (ie, lipoteichoic acid for 
CPS-A/B and DHG for CPS-C/D) [8, 24]. A  study evaluated 
the genetic diversity of E. faecalis strains and showed that half 
or more CPS-C strains appear to be more virulent than CPS-
A/B strains [10]. On the other hand, for E.  faecium several 
cell-surface associated proteins have been studied as antigens 
for vaccine development [11–13]. However, none of them have 
been evaluated for their dual role as a carrier protein for conju-
gation with a polysaccharide and as vaccine antigen.
In this work, we semisynthetized 2 enterococcal conjugates 
consisting of the immunogenic E. faecalis polysaccharide DHG 
and either PpiC or SagA, 2 immunogenic proteins of E. faecium. 
We demonstrated that DHG-PpiC and DHG-SagA not only 
induced polysaccharide specific antibodies toward DHG but 
also elicited antibodies against the protein immunogens. The 
resulting sera, α-DHG-PpiC and α-DHG-SagA, showed good 
and specific opsonophagocytic killing against both clinically 
relevant enterococcal species. We observed that the α-DHG-
protein sera had cross-reactive opsonophagocytic activities 
against E.  faecalis strains expressing the DHG polysaccharide 
and E. faecium strains expressing PpiC and SagA proteins.
Some bacterial strains cannot be evaluated by OPA be-
cause they can be susceptible to rabbit preimmune antibodies 
or to complement alone, while others undergo complement-
mediated phagocytosis. To further analyze the sera coverage, we 
performed whole-cell ELISA with a collection of 13 E. faecalis 
and 9 E.  faecium strains. Similar immunoreactivities toward 
E. faecalis strains were observed with α-DHG-protein sera when 
compared to α-DHG sera. For the E. faecium strains, sera raised 
against the conjugates showed reduced immunoreactivities in 
comparison to α-protein sera, which may be caused by the fact 
that the concentration was adjusted to the conjugate titers and 
not to protein titers. Lower immune responses have been also 
observed for protein carriers, since the conjugation process 
may affect immunogenic protein epitopes involved in the 
linkage of protein-polysaccharide molecules [34]. Nevertheless, 
α-DHG-protein sera had a broader immunoreactivity toward 
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Figure 6. Intravenous mouse infection model. Mice were passively immunized with the sera raised against DHG-PpiC (triangles) and DHG-SagA (squares) conjugates and 
challenged with Enterococcus faecalis type 2 and Enterococcus faecium 11236/1. After 48 hours of challenge, mice were euthanized, and their kidneys and livers were re-
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for the group. Statistical analysis was done by 1-way analysis of variance with the Dunnett post hoc test for comparison of the animals immunized with the antibodies raised 
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the enterococcal collection than the sera raised against the 
unconjugated antigens. Although immunoreactivity does not 
completely correlate with phagocytic killing, whole-cell ELISA 
can be used to determine whether the antigen/pathogen is rec-
ognized by antibodies [35].
There is renewed interest in studying the dual role (carrier/
protective antigen) of protein moieties in glycoconjugate vac-
cines to reduce vaccine formulation complexity, increase vac-
cine coverage, and simplify vaccination schedules [34, 36]. 
Dual-role carrier proteins have been studied in several bacterial 
pathogens, such as Streptococcus pneumoniae, Staphylococcus 
aureus, Clostridium difficile, Neisseria meningitidis, group B 
Streptococcus, Salmonella enterica, Klebsiella pneumoniae, and 
Pseudomonas aeruginosa [37–45]. In most of these studies, pro-
tein and polysaccharide from the same pathogen have been 
conjugated to increase either the protection and/or coverage 
against same bacterial species [37–45]. However, most of these 
studies have not assessed the potential cross-reactive coverage 
that this kind of glycoconjugates may have, since they evaluate 
1–2 strains for each part of the glycoconjugate but no larger 
strain collections. Cross-immunoreactivity was assessed only 
for N. meningitidis, K. pneumoniae, and P. aeruginosa, for 12, 
11, and 3 different bacterial strains, respectively [41, 45]. Only 1 
study has conjugated 2 antigens from different bacterial patho-
gens (ie, O-antigen from K. pneumoniae and flagellin proteins 
from P.  aeruginosa) to increase the coverage of the potential 
vaccine against gram-negative bacterial infections [45]. In our 
work, we conjugated antigens from the 2 most clinically relevant 
enterococcal species and immunized rabbits with the resulting 
glycoconjugates. The sera were evaluated by in vitro assays 
against 6 strains, whereas their cross-immunorecognition was 
tested against 23 enterococcal strains. Also, an in vivo infection 
model showed that the α-DHG-protein sera promoted clear-
ance of bacteria in mice livers (E. faecalis type 2 and E. faecium 
11236/1) and kidneys (E.  faecalis type 2), comparable to pre-
vious experiments with unconjugated antigens [8, 12, 13]. 
Nevertheless, further studies should assess whether these con-
jugates are more potent than the single antigens in the same 
animal models or if they offer protection in others (ie, rat endo-
carditis or urinary tract infection). Additionally, different con-
jugation strategies between DHG, SagA, and PpiC (ie, selective 
conjugation and noncovalent association), as well as the physi-
cochemical and immunological characterization of our carrier 
proteins, should be used to improve the immunogenicity of the 
glycoconjugates and to ensure their controlled production [34].
In summary, the glycoconjugates evaluated here are potential 
vaccine candidates that offer a broad coverage against infections 
caused by the 2 most clinically relevant enterococcal species. 
Furthermore, the SagA and PpiC proteins are promising immu-
nogenic carrier proteins that could be used either conjugated 
to DHG or to other polysaccharides to develop a multivalent 
vaccine against enterococci.
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